Test Update: General Chemistry and Immunoassay Testing

Effective February 10, 2019, PathGroup is pleased to announce the introduction of new testing equipment and methods for serum and plasma based general chemistry and immunoassay tests manufactured by the market leader in global clinical testing, Roche Diagnostics.


To read more, click here.

Test Update: Pan-TRK IHC Testing for Vitrakvi

Effective 3/4/2019

In late 2018, the FDA approved Vitrakvi® (larotrectinib) for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity and have no satisfactory alternative treatments or that have progressed following treatment.

PathGroup is pleased to announce the availability of Pan-TRK IHC (EPR17341) for this new indication. Orders within the SmartGenomics family of profiles will have TRK added based on the clinical context of the patient. The antibody is also available as a stand-alone immunohistochemistry test.


Click here for more information.

Test Update: General Chemistry Testing

On February 10, 2019, PathGroup introduced new automated clinical chemistry instrumentation manufactured by Roche Diagnostics. At that time, our reported reference ranges were based on Roche FDA cleared or approved product labeling and as validated in correlation studies performed at PathGroup.  Effective February 27 – 28, 2019, we have slightly modified the following test reference ranges in accordance with statistical analysis with our actual patient population.


For more information, click here.

Test Update: Urine Opiates Confirmation Testing

Effective January 14, 2019, PathGroup is pleased to introduce new LC/MS/MS methodology for the confirmation of urine opiates (Morphine, Oxymorphone, Hydromorphone, Codeine, Noroxycodone, Oxycodone, Hydrocodone, Norhydrocodone, and 6-Acetylmorphine).

For more information, click here.

2019 CPT Code Changes

Effective January 1, 2019, there will be CPT code changes for pathology and laboratory testing services provided by PathGroup.

For more information, CLICK HERE.



TEST UPDATE: Herpes Simplex Virus 1 and 2

Effective March 5, 2018, PathGroup has switched Herpes Simplex Virus 1 and 2 (HSV 1 & 2) detection from a laboratory developed Polymerase Chain Reaction (PCR) methodology to the FDA-approved Aptima HSV 1 & 2 Assay.

For more information, CLICK HERE

TEST UPDATE: Mycoplasma genitalium

Effective today, February 12, 2018, PathGroup offers testing for Mycoplasma genitalium, intended for use as an aid in the diagnosis of M. genitalium urogenital infections in male and female patients.

For more information, CLICK HERE